GSK plc GSK announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children aged ...
GSK : FDA Oks Menveo In Single-vial Presentation To Prevent Disease Caused By Meningococcal Bacteria
(RTTNews) - GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administrationhas approved Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria ...
Trump's room to wage war while maneuvering on economic policy is being tested by a force largely beyond his control: the bond market. Reuters, the news and media division of Thomson Reuters, is the ...
GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by bacterial ...
LONDON (Reuters) - GSK on Tuesday said that late-stage data showed its experimental combination meningococcal vaccine was as effective as two of its existing vaccines that target different strains of ...
Nearly three years after dosing the first patient in a phase 3 trial, GSK has now reported positive results from the trial of its much-anticipated combination meningitis vaccine. The shot, a ...
GSK has shared pivotal data that could help fend off Pfizer’s attack on its blockbuster vaccine franchise. The phase 3 results show the five-in-one meningitis vaccine is immunologically effective ...
GSK has received the Food and Drug Administration’s permission for Penmenvy (meningococcal groups A, B, C, W and Y vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results